FDA approves first vaccine for prevention of H5N1 avian influenza

Share this article:

 

The Food and Drug Administration has approved the first vaccine for the prevention of H5N1 influenza, which is commonly known as bird flu.

The vaccine is not intended for commercial availability, but the U.S. Department of Health and Human Services has purchased the vaccine from ID Biomedical Corporation of Quebec (a subsidiary of GlaxoSmithKline Biologicals) to hold within the National Stockpile. The vaccine is administered via intramuscular injection in two doses 21 days apart.

 

The H5N1 virus has been known to cause serious illness and death in people outside of the United States. Around 60% of people die once infected, according to the World Health Organization. H5N1 is considered to have pandemic potential because it infects wild birds with occasional outbreaks in poultry, and because most humans have no immunity against it. 

Share this article:

More in Products

Nurse technology contest seeks applications

Nurses who want to share the ways technology has led to a better student or patient outcome are invited to enter a contest that touts two $10,000 cash awards.

Accessory for swimming approved for cochlear implants

Accessory for swimming approved for cochlear implants ...

The Food and Drug Administration has approved the Aqua+ accessory, a waterproof, behind-the-ear product for cochlear implant recipients. The accessory allows Cochlear™ Nucleus® 5 and Nucleus 6 Implant recipients2 to ...

Non-Invasive Open Ventilation System approved

Non-Invasive Open Ventilation System approved

Breathe Technologies, which makes the Non-Invasive Open Ventilation (NIOV) System, said the Food and Drug Administration has granted the fifth 510(k) clearance for the product.